<?xml version="1.0" encoding="utf-8"?>
<html madcap:lastblockdepth="4" madcap:lastheight="878" madcap:lastwidth="701" xmlns:madcap="http://www.madcapsoftware.com/Schemas/MadCap.xsd">
 <head>
 </head>
 <body>
  <h1>
   Lupin Limited
  </h1>
  <div style="display: none;">
   <table cellspacing="1" class="TableStyle-dnb_tablestyle_1" style="mc-table-style: url('../Resources/TableStyles/dnb_tablestyle_1.css');">
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <thead>
     <tr class="TableStyle-dnb_tablestyle_1-Head-Header1">
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       DUNS
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       Hoovers ID
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadD-Column1-Header1">
       Tier
      </th>
     </tr>
    </thead>
    <tbody>
     <tr class="TableStyle-dnb_tablestyle_1-Body-Body1">
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
        650121635
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
       177739
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyA-Column1-Body1" style="text-align: center;">
       2
      </td>
     </tr>
    </tbody>
   </table></div><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Synopsis.flsnp" /><p>
   Lupin Limited is a pharmaceutical company that mainly targets the cardiovascular, anti-infective, and diabetology markets. Catering to the branded and generic markets in the US, the company's Suprax brand, a pediatric antibiotic used to treat throat and kidney problems, is its top-selling product in the country. Other chief products include Antara (cholesterol reduction), Locoid lotion (for topical use), Alinia (digestive problems), and InspiraChambers (antistatic valved holding chamber for delivery in the lungs). Overall, Lupin is among the market leaders within the cardiovascular (antituberculosis) market and caters to Europe, India, South Africa, and the US, among other regions.
  </p><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Geographic Reach.flsnp" />
  <p>
   In India, Lupin operates through 11 manufacturing plants. The drug firm has 28 international subsidiaries located in 15 countries and a joint venture in Japan. Representative offices reside in China, Kazakhstan, Russia, Ukraine, Uzbekistan, and Vietnam.
  </p>
  <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Operations.flsnp" />
  <p>
   Lupin's main product portfolio targets the analgesics, antibiotics, antigout, antituberculosis, cardiovascular, and central nervous system product lines.
  </p>
  <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Strategy.flsnp" />
  <p>
   Lupin has grown by acquiring other portfolios and introducing new products. In mid-2016 the drug firm entered the lucrative Japanese branded pharmaceutical market by acquiring 21 branded products from Japan's
   <company id="56875">
    Shionogi &amp; Co Ltd
   </company>
   . The acquired products covered therapy areas such as the central nervous system (CNS), oncology, cardiovascular, and anti-infectives.
  </p>
  <p>
   The company in 2016 announced that its subsidiary Gavis Pharmaceuticals had received final approval from US health regulators to market potassium chloride extended-release capsules within the American market. The products are used for treating potassium deficiency in the bloodstream.
  </p>
  <p>
   Also on its blueprint for growth, Lupin is targeting high-barrier niche segments such as inhalation, biosimilars, and complex injectables. Lupin has also recently launched three new manufacturing facilities in India to meet future market demand.
  </p>
 <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /></body>
</html>
